The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Open accessAbstract
OBJECTIVE: Assess Aβ deposition longitudinally and explore its relationship with cognition and disease progression. METHODS: Clinical follow-up was obtained 20 ± 3 months after [¹¹C]Pittsburgh compound B (PiB)-positron emission tomography in 206 subjects: 35 with dementia of the Alzheimer type (DAT), 65 with mild cognitive impairment (MCI), and 106 age-matched healthy controls (HCs). A second PiB scan was obtained at follow-up in 185 subjects and a third scan after 3 years in 57. RESULTS: At baseline, 97% of DAT, 69% of MCI, and 31% of HC subjects showed high PiB retention. At 20-month follow-up, small but significant increases in PiB standardized uptake value ratios were observed in the DAT and MCI groups, and in HCs with high PiB retention at baseline (5.7%, 2.1%, and 1.5%, respectively). Increases were associated with the number of apolipoprotein E ε4 alleles. There was a weak correlation between PiB increases and decline in cognition when all groups were combined. Progression to DAT occurred in 67% of MCI with high PiB versus 5% of those with low PiB, but 20% of the low PiB MCI subjects progressed to other dementias. Of the high PiB HCs, 16% developed MCI or DAT by 20 months and 25% by 3 years. One low PiB HC developed MCI. INTERPRETATION: Aβ deposition increases slowly from cognitive normality to moderate severity DAT. Extensive Aβ deposition precedes cognitive impairment, and is associated with ApoE genotype and a higher risk of cognitive decline in HCs and progression from MCI to DAT over 1 to 2 years. However, cognitive decline is only weakly related to change in Aβ burden, suggesting that downstream factors have a more direct effect on symptom progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and that progression of biomarker measures is also a continuous process that begins before symptoms [9–14]”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Numerous studies have shown that CU individuals with abnormal amyloid biomarkers have more rapid progression of atrophy, hypometabolism, and clinical/cognitive decline than individuals without biomarker evidence of Aβ deposition [13,33,80,93–99]”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ε4 allele increased brain amyloid burden in a dose-dependent manner in normal elderly individuals and in mild cognitive impairment patients [93,94].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [94]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a study characterizing sporadic AD, for instance, Villemagne et al. used Pittsburgh compound B (PiB) positron emission tomography (PET) to show that 31% of healthy control subjects had high PiB retention indicating Aß deposition and of these, 25% developed mild cognitive impairment or AD by 3 years (Villemagne et al., 2011).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Villemagne et al., 2011
In the citing paper
“Previous longitudinal studies have either failed to detect an early increase in regional Aβ deposition16 or identified a rather large early stage Aβ region including the posterior temporal, inferior parietal, posterior cingulate, precuneus, and occipital areas4.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Self-citationVitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Design and construction of a realistic digital brain phantom
Collins, D. L., Zijdenbos, A. P., Kollokian, V., Sled, J. G., Kabani, N. J., Holmes, C. J., & Evans, A. C. (1998) · IEEE Transactions on Medical Imaging · doi:10.1109/42.712135 · Cited by 1,825
Mitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Self-citationJack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 836
Serum and brain natural copper stable isotopes in a mouse model of Alzheimer’s disease
Moynier, F., Creech, J., Dallas, J., & Borgne, M. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-47790-5 · Cited by 50
Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition
Burnham, S. C., Laws, S. M., Budgeon, C. A., Doré, V., Porter, T., Bourgeat, P., Buckley, R. F., Murray, K., Ellis, K. A., Turlach, B. A., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.06.001 · Cited by 55
Self-citationPre‐diagnostic cognitive and functional impairment in multiple sporadic neurodegenerative diseases
Swaddiwudhipong, N., Whiteside, D. J., Hezemans, F. H., Street, D., Rowe, J. B., & Rittman, T. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12802 · Cited by 48
Neuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 55
Self-citationYang, J., Hu, C., Guo, N., Dutta, J., Vaina, L. M., Johnson, K. A., Sepulcre, J., Fakhri, G. E., & Li, Q. (2017) · Scientific Reports · doi:10.1038/s41598-017-13339-7 · Cited by 50
Advances in Brain Amyloid Imaging
Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 48
Self-citationRodríguez‐Ayllón, M., Solis‐Urra, P., Arroyo‐Avila, C., Álvarez-Ortega, M., Molina‐García, P., Molina‐Hidalgo, C., Gómez-Río, M., Brown, B. M., Erickson, K. I., & Esteban‐Cornejo, I. (2023) · Journal of sport and health science/Journal of Sport and Health Science · doi:10.1016/j.jshs.2023.08.001 · Cited by 50
Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid-β
Ellis, K. A., Lim, Y. Y., Harrington, K., Ames, D. J., Bush, A. I., Darby, D., Martins, R. N., Masters, C. L., Rowe, C. C., Savage, G. R., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122170 · Cited by 52
Self-citationMultimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load
Grothe, M. J., Villeneuve, S., Dyrba, M., Bartrés‐Faz, D., Wirth, M., Initiative, A. D. N., Initiative, A. D. N., Weiner, M. W., Aisen, P., Weiner, M. W., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003585 · Cited by 47
Self-citationCognitive and physical markers of prodromal dementia: A 12‐year‐long population study
Grande, G., Rizzuto, D., Vetrano, D. L., Marseglia, A., Vanacore, N., Laukka, E. J., Welmer, A., & Fratiglioni, L. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12002 · Cited by 46
Förster, S., Yousefi, B. H., Wester, H.-J., Klupp, E., Rominger, A., Förstl, H., Kurz, A., Grimmer, T., & Drzezga, A. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2230-9 · Cited by 45
Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies
Gomperts, S. N. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0472-6 · Cited by 47
Added Diagnostic Value of 11C-PiB-PET in Memory Clinic Patients with Uncertain Diagnosis
Frederiksen, K. S., Hasselbalch, S. G., Hejl, A., Law, I. G., Højgaard, L. D., & Waldemar, G. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000345783 · Cited by 46
Xia, Y., Eeles, E. M., Fripp, J., Pinsker, D. M., Thomas, P. A., Latter, M. J., Doré, V., Fazlollahi, A., Bourgeat, P., Villemagne, V. L., et al. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.102992 · Cited by 44
Self-citationDanshen diversity defeating dementia
Hügel, H., & Jackson, N. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.042 · Cited by 45
Ossenkoppele, R., Madison, C. M., Oh, H., Wirth, M., van Berckel, B. N. M., & Jagust, W. J. (2013) · Cerebral Cortex · doi:10.1093/cercor/bht076 · Cited by 45
Influence of amyloid and APOE on cognitive performance in a late middle‐aged cohort
Mielke, M. M., Machulda, M. M., Hagen, C. E., Christianson, T. J. H., Roberts, R. O., Knopman, D. S., Vemuri, P., Lowe, V. J., Kremers, W. K., Jack, C. R., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.09.010 · Cited by 48
Neuroimaging of Alzheimer’s disease: focus on amyloid and tau PET
Matsuda, H., Shigemoto, Y., & Sato, N. (2019) · Japanese Journal of Radiology · doi:10.1007/s11604-019-00867-7 · Cited by 50
Amyloid PET imaging in clinical practice
Kolanko, M., Win, Z., Loreto, F., Patel, N., Carswell, C. J., Gontsarova, A., Perry, R. J., & Malhotra, P. (2020) · Practical Neurology · doi:10.1136/practneurol-2019-002468 · Cited by 47
Mormino, E. C. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9267-4 · Cited by 44
Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials
Andrews, K. A., Marc Modat, A., Macdonald, K. E., Yeatman, T., Cardoso, M. J., Leung, K. K., Barnes, J., Villemagne, V. L., Rowe, C. C., Fox, N. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058816 · Cited by 48
Self-citationWitte, M. M., Foster, N. L., Fleisher, A., Williams, M., Quaid, K. A., Wasserman, M. R., Hunt, G., Roberts, J. S., Rabinovici, G. D., Levenson, J. L., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.06.006 · Cited by 44
Gu, Y., Razlighi, Q. R., Zahodne, L. B., Janicki, S. C., Ichise, M., Manly, J. J., Devanand, D. P., Brickman, A. M., Schupf, N., Mayeux, R. P., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123743 · Cited by 47
Rembach, A., the AIBL Research Group, Watt, A. D., Wilson, W. J., Villemagne, V. L., Burnham, S. C., Ellis, K. A., Maruff, P., Ames, D., Rowe, C. C., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131802 · Cited by 48
Self-citationEffects of age and β-amyloid on cognitive changes in normal elderly people
Oh, H., Madison, C. M., Haight, T. J., Markley, C., & Jagust, W. J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.008 · Cited by 42
Disclosure of amyloid imaging results to research participants: Has the time come?
Lingler, J. H., & Klunk, W. E. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.09.014 · Cited by 44
Self-citationQuevenco, F. C., Preti, M. G., Bergen, J. M. G. V., Hua, J., Wyss, M., Li, X., Schreiner, S. J., Steininger, S. C., Meyer, R., Meier, I. B., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0249-7 · Cited by 41
for the EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders, Drzezga, A. E., Altomare, D., Festari, C., Arbizu, J., Orini, S., Herholz, K., Nestor, P. J., Agosta, F., Bouwman, F. H., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4032-1 · Cited by 43
Ge, L., Liu, Z., & Tian, Y. (2020) · Chemical Science · doi:10.1039/c9sc05256a · Cited by 43
Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings
Braskie, M. N., & Thompson, P. M. (2013) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2013.08.007 · Cited by 48
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 55
Alzheimer’s disease: amyloid-based pathogenesis and potential therapies
Zhou, Y., Sun, Y., Ma, Q., & Liu, Y. (2018) · Cell Stress · doi:10.15698/cst2018.07.143 · Cited by 45
Nano-scientific Application of Atomic Force Microscopy in Pathology: from Molecules to Tissues
Kiio, T. M., & Park, S. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.41805 · Cited by 44
A Candidate Plasma Protein Classifier to Identify Alzheimer's Disease
Zhao, X., Lejnine, S., Spond, J., Zhang, C., Ramaraj, T. C., Holder, D., Dai, H. A., WEINER, R. S., & Laterza, O. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141149 · Cited by 43
Ye, B. S., Kim, Y. J., Kim, Y. J., Jung, N., Lee, J. S., Lee, J., Jang, Y. K., Yang, J., Lee, J. M., Vogel, J. W., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23676-w · Cited by 41
Evaluation of neuroprotective effect of glucagon‐like peptide 1 analogs using neuroimaging
Femminella, G. D., & Edison, P. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.012 · Cited by 43
Visuospatial dysfunction in Alzheimer's disease and behavioural variant frontotemporal dementia
Salimi, S., Irish, M., Foxe, D., Hodges, J. R., Piguet, O., & Burrell, J. R. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.04.019 · Cited by 40
Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks
Petersen, K. K., Milà‐Alomà, M., Li, Y., Du, L., Xiong, C., Tosun, D., Saef, B. A., Saad, Z. S., Du‐Cuny, L., Coomaraswamy, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04206-y · Cited by 51
Durazzo, T. C., Mattsson, N., Weiner, M. W., & Initiative, A. D. N. (2015) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntv075 · Cited by 41
Thai, C., Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D. J., Ellis, K. A., Rainey‐Smith, S. R., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139082 · Cited by 40
Self-citationLim, Y. Y., Williamson, R., Laws, S. M., Villemagne, V. L., Bourgeat, P., Fowler, C. J., Rainey‐Smith, S. R., Salvado, O., Martins, R. N., Rowe, C. C., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170072 · Cited by 41
Self-citationThe Interaction Between Neuroinflammation and β-Amyloid in Cognitive Decline in Parkinson’s Disease
Ghadery, C., Koshimori, Y., Christopher, L., Kim, J., Rusjan, P., Lang, A. E., Houle, S., & Strafella, A. P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01714-6 · Cited by 42
Norton, D. J., Parra, M. A., Sperling, R. A., Baena, A. Y., Guzmán‐Vélez, E., Jin, D. S., Andrea, N., Khang, J., Schultz, A. P., Rentz, D. M., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00660-z · Cited by 40
Contributions of Academic Laboratories to the Discovery and Development of Chemical Biology Tools
Huryn, D. M., Resnick, L., & Wipf, P. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400132d · Cited by 40
When the infectious environment meets the AD brain
Ganz, T., Fainstein, N., & Ben-Hur, T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00559-3 · Cited by 39
Positron Emission Tomographic Imaging in Stroke
Sahathevan, R., Linden, T. K. A., Villemagne, V. L., Churilov, L. P., Ly, J. V., Rowe, C. C., Donnan, G. A., & Brodtmann, A. G. (2015) · Stroke · doi:10.1161/strokeaha.115.010528 · Cited by 41
Self-citationSalerno, M., & Porqueras, D. S. D. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.04.018 · Cited by 41
Nedelská, Z., Schwarz, C. G., Lesnick, T. G., Boeve, B. F., Przybelski, S. A., Lowe, V. J., Kremers, W. K., Gunter, J. L., Senjem, M. L., Graff‐Radford, J., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.16439 · Cited by 38
Lim, Y. Y., Ellis, K. A., Harrington, K., Kamer, A., Pietrzak, R. H., Bush, A. I., Darby, D., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2013) · Neuropsychology · doi:10.1037/a0032321 · Cited by 41
Self-citationPettigrew, C., Soldan, A., Moghekar, A., Wang, M.-C., Gross, A. L., O’Brien, R., & Albert, M. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.09.024 · Cited by 38
Carbone, M. G., Pagni, G., Tagliarini, C., Imbimbo, B. P., & Pomara, N. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101420 · Cited by 39
Guerra, U. P., Nobili, F. M., Padovani, A., Perani, D., Pupi, A., Sorbi, S., & Trabucchi, M. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2079-3 · Cited by 38
Five-year follow-up of 11C-PIB uptake in Alzheimer’s disease and MCI
Kemppainen, N. M., Scheinin, N. M., Koivunen, J., Johansson, J. J., Toivonen, J., Någren, K., Rokka, J., Karrasch, M., Parkkola, R. K., & Rinne, J. O. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2562-0 · Cited by 40
Adiponectin Role in Neurodegenerative Diseases: Focus on Nutrition Review
Polito, R., Meo, I. D., Barbieri, M., Daniele, A., Paolisso, G., & Rizzo, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239255 · Cited by 39
PET Agents in Dementia: An Overview
van Waarde, A., Marcolini, S., Deyn, P. P. D., & Dierckx, R. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.008 · Cited by 39
Insulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses
Alves, S. S., da Silva-Júnior, R. M. P., Servilha‐Menezes, G., Homolak, J., Šalković‐Petrišić, M., & Garcia‐Cairasco, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210234 · Cited by 39
Ye, Q., Su, F., Gong, L., Shu, H., Liao, W., Xie, C., Zhou, H., Zhang, Z., & Bai, F. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00288 · Cited by 39
The neurobiology of Alzheimer disease defined by neuroimaging
Masdeu, J. C., Kreisl, W. C., & Berman, K. F. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283557b36 · Cited by 39
APOE4 predicts amyloid-β in cortical brain biopsy but not idiopathic normal pressure hydrocephalus
Pyykkö, O. T., Helisalmi, S., Koivisto, A. M., Mölsä, J. A. A., Rummukainen, J. K., Nerg, O., Alafuzoff, I. I., Savolainen, S., Soininen, H. S., Jääskeläinen, J. E., et al. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-303849 · Cited by 38
Joshi, Y. B., Giannopoulos, P. F., Chu, J., Sperow, M., Kirby, L. G., Abood, M. E., & Praticò, D. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu412 · Cited by 37
RetractedPorter, T., Burnham, S. C., Doré, V., Savage, G. R., Bourgeat, P., Begemann, K., Milicic, L., Ames, D. J., Bush, A. I., Maruff, P. T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20513-y · Cited by 36
Self-citationOcular Biomarkers of Alzheimer's Disease: The Role of Anterior Eye and Potential Future Directions
Dehghani, C., Frost, S. M., Jayasena, R., Masters, C. L., & Kanagasingam, Y. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24694 · Cited by 37
Self-citationPorter, T., Burnham, S. C., Savage, G. R., Lim, Y. Y., Maruff, P. T., Milicic, L., Peretti, M., Ames, D. J., Masters, C. L., Martins, R. N., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00423 · Cited by 38
Self-citationZinc-mediated Neurotransmission in Alzheimer's Disease: A Potential Role of the GPR39 in Dementia
Rychlik, M., & Młyniec, K. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190704153807 · Cited by 37
Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions
Rowley, P. A., Samsonov, A. A., Betthauser, T. J., Pirasteh, A., Johnson, S. C., & Eisenmenger, L. B. (2020) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2020.08.011 · Cited by 40
Aschenbrenner, A. J., Balota, D. A., Fagan, A. M., Duchek, J. M., Benzinger, T. L. S., & Morris, J. C. (2015) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617715000776 · Cited by 37
Imaging microglial activation and amyloid burden in amnestic mild cognitive impairment
Knezevic, D., Verhoeff, N. P. L. G., Hafizi, S., Strafella, A. P., Graff‐Guerrero, A., Rajji, T. K., Pollock, B. G., Houle, S., Rusjan, P., & Mizrahi, R. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17741395 · Cited by 38
Use of ocular biomarkers as a potential tool for early diagnosis of Alzheimer's disease
Singh, A., & Verma, S. (2020) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_999_19 · Cited by 36
Quevenco, F. C., Bergen, J. M. G. V., Treyer, V., Studer, S. T., Kagerer, S. M., Meyer, R., Gietl, A. F., Kaufmann, P. A., Nitsch, R. M., Höck, C., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00046 · Cited by 34
Bahar‐Fuchs, A., Villemagne, V. L., Ong, K. T., Chételat, G., Lamb, F., Reininger, C. B., Woodward, M., & Rowe, C. C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121315 · Cited by 36
Self-citationThe association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI
Harrington, K., Lim, Y. Y., Ellis, K. A., Copolov, C., Darby, D., Weinborn, M., Ames, D. J., Martins, R. N., Savage, G. R., Szoeke, C. E. I., et al. (2013) · International Psychogeriatrics · doi:10.1017/s1041610213001087 · Cited by 36
Self-citationTudorascu, D., Minhas, D. S., Lao, P. J., Betthauser, T. J., Yu, Z., Laymon, C. M., Lopresti, B. J., Mathis, C. A., Klunk, W. E., Handen, B. L., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.03.006 · Cited by 35
Self-citationMelatonin attenuates streptozotocin-induced Alzheimer-like features in hyperglycemic rats
Kamsrijai, U., Wongchitrat, P., Nopparat, C., Satayavivad, J., & Govitrapong, P. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104601 · Cited by 37
Lim, Y. Y., Ellis, K. A., Harrington, K., Pietrzak, R. H., Gale, J., Ames, D. J., Bush, A. I., Darby, D., Martins, R. N., Masters, C. L., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121771 · Cited by 38
Self-citationCerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease
Wang, F., Gordon, B. A., Ryman, D. C., Ma, S., Xiong, C., Hassenstab, J. J., Goate, A., Fagan, A. M., Cairns, N. J., Marcus, D. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001903 · Cited by 34
Self-citationThe prognostic value of amyloid imaging
Gelosa, G., & Brooks, D. J. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2108-x · Cited by 35
Henderson, T. A. (2012) · CNS Spectrums · doi:10.1017/s1092852912000636 · Cited by 37
APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points
Toledo, J. B., Habes, M., Sotiras, A., Bjerke, M., Yong Fan, A., Weiner, M. W., Shaw, L. M. J., Davatzikos, C. A., Trojanowski, J. Q., & Initiative, A. D. N. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181282 · Cited by 36
Morphometric Changes to Corneal Dendritic Cells in Individuals With Mild Cognitive Impairment
Dehghani, C., Frost, S. M., Jayasena, R., Fowler, C. J., Masters, C. L., Kanagasingam, Y., Jiao, H., Lim, J. K. H., Chinnery, H. R., & Downie, L. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.556137 · Cited by 34
Self-citationDeCarli, C. S., Villeneuve, S., Maillard, P., Harvey, D. J., Singh, B., Carmichael, O. T., Fletcher, E. M., Olichney, J., Farias, S. T., Jagust, W. J., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180965 · Cited by 33
APOE ε4 influences β‐amyloid deposition in primary progressive aphasia and speech apraxia
Josephs, K. A., Duffy, J. R., Strand, E. A., Machulda, M. M., Senjem, M. L., Lowe, V. J., Jack, C. R., & Whitwell, J. L. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.03.004 · Cited by 33
Early Indications of Future Cognitive Decline: Stable versus Declining Controls
Rizk‐Jackson, A., Insel, P. S., Petersen, R. C., Aisen, P. S. S., Jack, C. R., & Weiner, M. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074062 · Cited by 34
Application of CRISPR genetic screens to investigate neurological diseases
So, R. W. L., Chung, S., Lau, H. H. C., Watts, J. J., Gaudette, E. V., Al‐Azzawi, Z. A. M., Bishay, J., Lin, L. T., Joung, J., Wang, X., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0343-3 · Cited by 37
The impact of aging in dementia: It is time to refocus attention on the main risk factor of dementia
Mecocci, P., & Boccardi, V. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101210 · Cited by 39
Laczó, M., Martinkovič, L., Lerch, O., Wiener, J. M., Kalinová, J., Matušková, V., Nedelská, Z., Vyhnálek, M., Hort, J., & Laczó, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.886778 · Cited by 34
Synthesis and preliminary evaluation of 2‐arylhydroxyquinoline derivatives for tau imaging
Tago, T., Furumoto, S., Okamura, N., Harada, R., Ishikawa, Y., Arai, H., Yanai, K., Iwata, R., & Kudo, Y. (2013) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3133 · Cited by 32
Disrupted topology of the resting state structural connectome in middle-aged APOE ε4 carriers
Korthauer, L. E., Zhan, L., Ajilore, O., Leow, A., & Driscoll, I. F. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.05.052 · Cited by 31
Teipel, S. J., Dyrba, M., Chiesa, P. A., Sakr, F. A., Jelistratova, I., Lista, S., Vergallo, A., Lemercier, P., Cavedo, E., Habert, M. O., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.011 · Cited by 32
Nonlinear biomarker interactions in conversion from mild cognitive impairment to Alzheimer's disease
Popescu, S. G., Whittington, A., Gunn, R. N., Matthews, P. M., Glocker, B., Sharp, D. J., Cole, J. H., & Initiative, A. D. N. (2020) · Human Brain Mapping · doi:10.1002/hbm.25133 · Cited by 30
Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers
Chételat, G., & Fouquet, M. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.025 · Cited by 32
Self-citationten Kate, M., Barkhof, F., Visser, P. J., Teunissen, C. E., Scheltens, P., van der Flier, W. M., & Tijms, B. M. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0299-x · Cited by 33
Emerging insights into the role of albumin with plasma exchange in Alzheimer’s disease management
Costa, M., & Páez, A. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103164 · Cited by 32
Sun, Q., Ni, J., Wei, M., Long, S., Li, T., Fan, D., Lü, T., Shi, J., & Tian, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.963845 · Cited by 31
Biomarkers in Alzheimer’s Disease
Riverol, M., & López, O. L. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00046 · Cited by 33
Wildburger, N. C., Gyngard, F., Guillermier, C., Patterson, B. W., Elbert, D. L., Mawuenyega, K. G., Schneider, T., Green, K., Roth, R. A., Schmidt, R. E., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00169 · Cited by 32
Sun, Y., Lin, J., & Zhang, L. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.12.59 · Cited by 31
Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories
Lopresti, B. J., Campbell, E. M., Yu, Z., Anderson, S., Cohen, A. D., Minhas, D. S., Snitz, B. E., Royse, S. K., Becker, C. R., Aizenstein, H. J., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.05.012 · Cited by 32
Self-citationVillemagne, V. L., & Rowe, C. C. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211000895 · Cited by 30
Self-citationHuszár, Z., Engh, M. A., Pavlekovics, M., Sato, T., Steenkamp, Y., Hanseeuw, B. J., Terebessy, T., Molnár, Z., Hegyi, P., & Csukly, G. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01455-2 · Cited by 30
Imaging Brain Metabolism and Pathology in Alzheimer ’s Disease with Positron Emission Tomography
D, R. W. C. (2014) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000143 · Cited by 31
Metadata
- Authors
- Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., Martins, R., O'Keefe, G., Mathis, C. A., Klunk, W. E., Ames, D., Masters, C. L., & Rowe, C. C.
- Affiliations
- Mental Health Research Institute (AU)
- Austin Health (AU)
- Commonwealth Scientific and Industrial Research Organisation (AU)
- Australian e-Health Research Centre (AU)
- Edith Cowan University (AU)
- University of Pittsburgh (US)
- National Ageing Research Institute (AU)
- The University of Melbourne (AU)
- Corresponding author
- Villemagne, Victor L.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-01
- Volume
- 69
- Issue
- 1
- Pages
- 181-192
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC3045039
- OpenAlex
- W2051489981
- Cited by
- 833
- References
- 42
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 26 · 2023: 51 · 2022: 42 · 2021: 44 · 2020: 57 · 2019: 60 · 2018: 57 · 2017: 57 · 2016: 60 · 2015: 61 · 2014: 68 · 2013: 86 · 2012: 71
- FWCI
- 57.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Edith Cowan University Research Online (Edith Cowan University) (submittedVersion)
- Funders
- National Institute on Aging (P01AG025204, RF1AG025516, P50AG005133, R37AG025516)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- amyloid-beta deposition, Alzheimer's disease, mild cognitive impairment, Pittsburgh compound B PET, APOE ε4, cognitive decline, disease progression, aging
- MeSH terms
- Aged, Aging, Alzheimer Disease, Aniline Compounds, Brain, Cognition, Cognition Disorders, Female, Follow-Up Studies, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Neuropsychological Tests, Polymorphism, Genetic, Severity of Illness Index, Thiazoles, Amyloid beta-Peptides, Disease Progression, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
